ArticleEndocrine pathology1996
Assessment of Mitotic Activity in Pituitary Adenomas and Carcinomas.
Article in Endocrine pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Endothelial cell-specific molecule-1 as an invasiveness marker for pituitary null cell adenoma.BMC endocrine disorders · 2019Article
- Pediatric Pituitary Adenoma: Case Series, Review of the Literature, and a Skull Base Treatment Paradigm.Journal of neurological surgery. Part B, Skull base · 2018Review
- Histological criteria for atypical pituitary adenomas - data from the German pituitary adenoma registry suggests modifications.Acta neuropathologica communications · 2015Article
- Pituitary carcinoma with fourth ventricle metastasis: treatment by excision and Gamma-knife radiosurgery.Pituitary · 2014Article
- Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma.Brain pathology (Zurich, Switzerland) · 2012Article
- MAP-2 expression in the human adenohypophysis and in pituitary adenomas. An immunohistochemical study.Pituitary · 2005Article
- Prognostic indicators in pituitary tumors.Endocrine pathology · 2005Review
- Non-functioning pituitary carcinoma.Pituitary · 2004Article
- Best Practice No 172: pituitary gland pathology.Journal of clinical pathology · 2003Review
- Pituitary carcinoma: report of an exceptional case and review of the literature.Journal of endocrinological investigation · 2002Review
- Corticotroph pituitary carcinoma: case report and literature review.Endocrine pathology · 2001Review
- Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.Endocrine pathology · 2000Article
- Malignant pituitary tumours.Pituitary · 1998Review
- Adrenocorticotropin-Producing Pituitary Carcinoma with Expression of c-erbB-2 and High PCNA Index: A Comparative Study with Pituitary Adenomas and Normal Pituitary Tissues.Endocrine pathology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of mitotic activity represents one of the oldest and most routinely used histopathologic methods of evaluating the biological aggressiveness of human tumors. In the case of pituitary tumors, however, the relevance of this approach as a means of gauging tumor behavior remains ill-defined. In this article, the relationship between the mitotic index and biological aggressiveness of pituitary tumors was evaluated in a series of 54 pituitary adenomas and 6 primary pituitary carcinomas. All tumors were fully classified by immunohistochemistry and electron microscopy; adenomas were further stratified on the basis of their invasion status, the latter being defined as gross, operatively, or radiologically apparent infiltration of dura or bone. Mitotic figures were present in 11 tumors, 10 being either invasive adenomas or pituitary carcinomas. A significant association between the presence of mitotic figures and tumor behavior was noted, as evidenced by progressive increments in the proportion of cases expressing mitotic figures in the categories of noninvasive adenoma, invasive adenoma, and pituitary carcinoma (3.9, 21.4, and 66.7%, respectively; Fisher's exact test, two-tailed, p < 0.001). The mitotic index, however, appeared to be a less informative parameter, being extremely low in all cases (mean = 0.016% +/- 0.005 [+/- SEMI). Although the mean mitotic index in pituitary carcinomas (0.09% +/- 0.035) was significantly higher than the mean mitotic index of either noninvasive adenomas (0.002% +/- 0.002) or invasive adenomas (0.013% +/- 0.005), no practical threshold value capable of distinguishing these three groups was evident. Comparison of the mitotic index with Ki-67 derived growth fractions in these tumors revealed a significant but weak linear correlation (r = 0.41, p < 0.01). These data suggest that when, mitotic figures are present, they do provide some indication of the behavior and invasive potential of pituitary tumors. For routine diagnostic purposes, however, the discriminating power of this parameter is somewhat limited, being superseded by alternative and more informative methods of growth fraction determination such as that provided by the Ki-67 immunolabeling.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.